Tuesday, February 9, 2016
Gilead Sciences has announced that, effective March 10, current Chairman and CEO John C. Martin, Ph.D. will assume the role of executive chairman of the company. John F. Milligan, Ph.D., currently president and chief operating officer, will be promoted to CEO and appointed to the company’s board of directors.
GuideStar Clinical Trials Management, a company providing support services and strategies for clinical research programs around the U.S., and the Alliance for Clinical Research Excellence and Safety (ACRES), a multi-sector, nonprofit organization building a multi-stakeholder-driven integrated global system for clinical research, have partnered to expand site accreditation and uniformity across the clinical research community to promote and reward excellence.
MediSapiens, a Finnish developer and provider of Bio-IT solutions for research and biomedicine, is a partner in an international consortium aiming at developing personalized medicine applications using integrated genome and other health data. The consortium was founded and is headed by the Competence Centre on Health Technologies of Estonia (CCHT) in the framework of the Competence Centre program supported via Enterprise Estonia. Along with MediSapiens and CCHT, the other consortium members are the University of Tartu Estonian Genome Center (Estonia), Tallinn University of Technology eMedicine Laboratory (Estonia), BioEximi OÜ (Estonia), Duodecim Medical Publications Ltd. (Finland) and Coimbra Genomics (Portugal).
The Alliance for Clinical Research Excellence and Safety (ACRES), a global public-interest collaboration building a comprehensive system to transform clinical research, has announced a major second step toward full implementation of a multi-stakeholder shared information technology platform.
While drug developers during the coming year will continue their efforts to meet the growing demand for innovative new medicines, they also must significantly scale up their level of process improvements if they are to reduce the time and cost required to bring new drugs to market, according to the Tufts Center for the Study of Drug Development (CSDD).
Icon, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has launched Flex Advantage, a next-generation Interactive Response Technology (IRT) platform that offers enhanced randomization and clinical supply management capabilities and supports the execution of adaptive trials.
Research sponsors implement at least one substantial global amendment for nearly 60% of all clinical trial protocols, substantially reducing the number of actual patients screened and enrolled, but leading to significantly longer clinical trial durations and higher costs, a newly completed analysis by the Tufts Center for the Study of Drug Development (CSDD) concludes.
Certara, a global biosimulation technology-enabled drug development company, has launched Certara Strategic Consulting China in Shanghai. This new company is being led by President and CEO Christine Yuying Gao, M.D., Ph.D., former vice president of consulting services at Quantitative Solutions, a global pharmacometrics consulting company. Quantitative Solutions merged with Certara’s Pharsight Consulting Services in July 2015 to form Certara Strategic Consulting.